Zhang W, Dong J, Wu Y, Liang X, Suo L, Wang L
Biochem Genet. 2024; .
PMID: 38833082
DOI: 10.1007/s10528-024-10840-3.
Wang T, Zhang F, Zhang P
Exp Ther Med. 2023; 25(6):304.
PMID: 37229326
PMC: 10203914.
DOI: 10.3892/etm.2023.12003.
Di Sotto A, Gulli M, Minacori M, Mancinelli R, Garzoli S, Percaccio E
Biomedicines. 2022; 10(9).
PMID: 36140359
PMC: 9496176.
DOI: 10.3390/biomedicines10092257.
Athira K, Gopakumar G
Mol Genet Genomics. 2022; 297(6):1467-1479.
PMID: 35922530
DOI: 10.1007/s00438-022-01932-z.
Xia X, Li Y
Transl Cancer Res. 2022; 9(10):6050-6061.
PMID: 35117216
PMC: 8797465.
DOI: 10.21037/tcr-20-704.
Identification of prognostic markers by weighted gene co-expression network analysis in non-small cell lung cancer.
Chen B, Xie X, Lan F, Liu W
Bioengineered. 2021; 12(1):4924-4935.
PMID: 34369264
PMC: 8806742.
DOI: 10.1080/21655979.2021.1960764.
RNA sequencing identified novel target genes for in breast and colon cancer cells.
El-Masry O, Goja A, Rateb M, Owaidah A, Alsamman K
Sci Prog. 2021; 104(3):368504211032084.
PMID: 34251294
PMC: 10450698.
DOI: 10.1177/00368504211032084.
High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability.
Matson D, Denu R, Zasadil L, Burkard M, Weaver B, Flynn C
BMC Cancer. 2021; 21(1):186.
PMID: 33622270
PMC: 7901195.
DOI: 10.1186/s12885-021-07893-7.
Key Genes and Prognostic Analysis in HER2+ Breast Cancer.
Weng Y, Liang W, Ji Y, Li Z, Jia R, Liang Y
Technol Cancer Res Treat. 2021; 20:1533033820983298.
PMID: 33499770
PMC: 7844453.
DOI: 10.1177/1533033820983298.
Overexpression of TPX2 predicts poor clinical outcome and is associated with immune infiltration in hepatic cell cancer.
Zhu H, Liu J, Feng J, Zhang Q, Bian T, Li X
Medicine (Baltimore). 2020; 99(49):e23554.
PMID: 33285774
PMC: 7717782.
DOI: 10.1097/MD.0000000000023554.
iMOKA: k-mer based software to analyze large collections of sequencing data.
Lorenzi C, Barriere S, Villemin J, Dejardin Bretones L, Mancheron A, Ritchie W
Genome Biol. 2020; 21(1):261.
PMID: 33050927
PMC: 7552494.
DOI: 10.1186/s13059-020-02165-2.
Investigating the Role of Telomere and Telomerase Associated Genes and Proteins in Endometrial Cancer.
Bradfield A, Button L, Drury J, Green D, Hill C, Hapangama D
Methods Protoc. 2020; 3(3).
PMID: 32899298
PMC: 7565490.
DOI: 10.3390/mps3030063.
Comprehensive analysis of prognosis-related methylated sites in breast carcinoma.
Li J, Li X
Mol Genet Genomic Med. 2020; 8(4):e1161.
PMID: 32037691
PMC: 7196449.
DOI: 10.1002/mgg3.1161.
Identification of differentially expressed genes in non-small cell lung cancer.
Wang K, Chen R, Feng Z, Zhu Y, Sun X, Huang W
Aging (Albany NY). 2019; 11(23):11170-11185.
PMID: 31816603
PMC: 6932904.
DOI: 10.18632/aging.102521.
Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma.
Zhang H, Zou J, Yin Y, Zhang B, Hu Y, Wang J
PeerJ. 2019; 7:e8096.
PMID: 31788359
PMC: 6883955.
DOI: 10.7717/peerj.8096.
Integrated bioinformatics analysis to identify 15 hub genes in breast cancer.
Jin H, Huang X, Shao K, Li G, Wang J, Yang H
Oncol Lett. 2019; 18(2):1023-1034.
PMID: 31423162
PMC: 6607081.
DOI: 10.3892/ol.2019.10411.
Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival.
Nair N, Das A, Rogkoti V, Fokkelman M, Marcotte R, de Jong C
Sci Rep. 2019; 9(1):10989.
PMID: 31358840
PMC: 6662662.
DOI: 10.1038/s41598-019-47440-w.
Identification of five hub genes as monitoring biomarkers for breast cancer metastasis in silico.
Cai Y, Mei J, Xiao Z, Xu B, Jiang X, Zhang Y
Hereditas. 2019; 156:20.
PMID: 31285741
PMC: 6588910.
DOI: 10.1186/s41065-019-0096-6.
Prognostic Genes of Breast Cancer Identified by Gene Co-expression Network Analysis.
Tang J, Kong D, Cui Q, Wang K, Zhang D, Gong Y
Front Oncol. 2018; 8:374.
PMID: 30254986
PMC: 6141856.
DOI: 10.3389/fonc.2018.00374.
Overexpression of TPX2 is associated with progression and prognosis of prostate cancer.
Zou J, Huang R, Jiang F, Chen D, Wang C, Han Z
Oncol Lett. 2018; 16(3):2823-2832.
PMID: 30127868
PMC: 6096215.
DOI: 10.3892/ol.2018.9016.